Milatuzumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Milatuzumab
Accession Number
DB12943
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Milatuzumab has been used in trials studying the treatment of Lupus Nephritis, Multiple Myeloma (MM), GVHD (Acute or Chronic), Myelodysplastic Syndrome, and Chronic Lymphocytic Leukemia, among others.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
Categories
UNII
2OP4E0GC6V
CAS number
899796-83-9

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Milatuzumab.
AbituzumabThe risk or severity of adverse effects can be increased when Abituzumab is combined with Milatuzumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Milatuzumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Milatuzumab.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Milatuzumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Milatuzumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Milatuzumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Milatuzumab.
AmatuximabThe risk or severity of adverse effects can be increased when Amatuximab is combined with Milatuzumab.
AMG 108The risk or severity of adverse effects can be increased when AMG 108 is combined with Milatuzumab.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911409
Wikipedia
Milatuzumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentAcute Myeloid or Lymphoblastic Leukemia (AML or ALL) / Chronic Chronic myelogenous leukemia / Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL) / GVHD (Acute or Chronic) / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell)1
1, 2CompletedTreatmentChronic Lymphocytic Lymphoma1
1, 2CompletedTreatmentMalignant Lymphomas1
1, 2CompletedTreatmentMultiple Myeloma (MM) / Myeloma, Plasma-Cell / Plasmacytoma1
1, 2RecruitingTreatmentLupus Erythematosus, Cutaneous / Lupus Erythematosus, Discoid / Lupus Erythematosus, Systemic / Lupus Vasculitis, Central Nervous System / Nephritis, Lupus1
1, 2Unknown StatusTreatmentChronic Lymphocytic Leukaemia (CLL)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 19:30 / Updated on November 02, 2018 07:31